Nebivolol Ab (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑blocker used in cardiovascular therapy, primarily to control blood pressure and improve heart function.

• Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension.
• Heart failure: reduces mortality and hospitalisation in adults with chronic heart failure.
• Reduced left ventricular ejection fraction: improves cardiac output in patients with decreased ejection fraction due to heart failure.

• Nebivolol Hydrochloride binds selectively to β1‑adrenergic receptors, blocking catecholamine‑induced stimulation of heart rate and contractility. In parallel, it enhances endothelial nitric‑oxide synthase activity, leading to nitric‑oxide‑mediated vasodilation. The combined effect reduces systemic vascular resistance and myocardial oxygen demand, resulting in lowered arterial pressure and improved cardiac efficiency in heart‑failure states.

Nebivolol is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Dizziness or light‑headedness: especially upon standing.
• Fatigue: feeling unusually tired or weak.
• Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects

• Bradycardia: abnormally slow heart rate requiring medical assessment.
• Severe hypotension: marked drop in blood pressure that may cause fainting.
• Bronchospasm: airway narrowing, particularly in patients with reactive airway disease.

Nebivolol should be used with caution in specific clinical situations.

• Cardiovascular disease: assess baseline heart rate and blood pressure before initiation.
• Renal impairment: dose adjustment may be needed in patients with reduced kidney function.
• Hepatic impairment: monitor liver enzymes and consider dose modification.
• Concomitant β‑blockers: avoid additive effects that could cause excessive bradycardia.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Nebivolol may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): can markedly increase nebivolol plasma levels.
• Non‑selective β‑blockers: combined use may cause profound bradycardia and hypotension.
• Severe bradyarrhythmias: concurrent use can exacerbate heart‑rate slowing.

Moderate Interactions (Monitor Closely):\n- Calcium‑channel blockers (e.g., amlodipine): may enhance antihypertensive effect.

• Diuretics: additive blood‑pressure lowering, monitor electrolytes.
• Other antihypertensives: dose titration may be required to avoid excessive hypotension.